Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10145 - 10152 of 12144 results

Court Dismisses Shareholder Derivative Action Targeting Directors and Officers for Data Breaches
October 22, 2014| Blog| Viewpoint

GAO Releases Report on CPSC Response to New and Emerging Hazards
October 21, 2014| Blog| Viewpoint

Inter Partes Review Initial Filings of Paramount Importance: What Is Clear After Two Years of Inter Partes Review Under the AIA
October 21, 2014| Advisory| Viewpoint

Join Our Webinar on Protecting Directors from Liability for Cybersecurity Risks
October 21, 2014| Blog| Viewpoint

Electronically Signing USPTO Papers: There’s a Rule for That
October 20, 2014| Blog| Viewpoint

Business Interruption Insurance for Ebola – Managing Risk for Hospitals and Healthcare Providers
October 20, 2014| Blog| Viewpoint

Supreme Court Examines Boundaries of Antitrust Immunity
October 20, 2014| Blog| Viewpoint

Keep Your Hands Off the Customers … and the Cows
October 17, 2014| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
